Lundbeck sees big sales from new bipolar drug; Actelion nominees deny M&A focus;

@FiercePharma: Will KV's 55% Makena price cut satisfy critics? Item | Follow @FiercePharma

> Danish drugmaker Lundbeck said it was launching a new bipolar disorder drug licensed from Merck, predicting considerable sales in the future. Report

> A group of prospective Actelion board members denied speculation they planned to prepare Europe's biggest biotech for sale and said they instead wanted to overhaul it. News

> A fire at Roche's warehouse in Törökbalint, Hungary, damaged all of the medicines stored there, the Swiss-owned drugmaker said. Item

> Antidepressants may narrow the arteries of middle-aged men, potentially putting them at risk for heart attacks and stroke, researchers said. Article

> Depomed said its president and CEO, Carl Pelzel, resigned for personal reasons and will be replaced by board member James Schoeneck. Report

> Dutch pharma-tech company Qiagen said it would buy Australian drugmaker Cellestis for $341 million, or $3.55 a share. Item

> Dr Reddy's Laboratories said its U.S. subsidiary Promius Pharma will collaborate with Valeant Pharmaceuticals to manufacture and market Cloderm cream in the American market. Story

> Construction of a proposed industrial park in Bangladesh for manufacturing pharmaceutical ingredients will complete by 2012, a government minister said. Report

> The pharmaceutical manufacturing sector in Puerto Rico will thrive because of and not in spite of changes to the country's tax and incentive laws, the Puerto Rico Industrial Development Company said. News

> From a company with annual sales of $400 million in 2007, India's Zydus Cadila has become a $1 billion firm. Item

Biotech News

 @FierceBiotech: Ahead of panel, FDA staffers back Optimer's antibiotic fidaxomicin. Report | Follow @FierceBiotech 

 @JohnCFierce: Tranzyme raised $48M in its IPO, but only after almost tripling the number of shares and slashing the price. Story | Follow @JohnCFierce

> Westphal leaving SR One, concentrating on VC firm. News

> Tranzyme rips up old IPO plan as it goes public. Story

> 10 promising late-stage cancer drugs. News 

> Vivus surges on fresh batch of promising obesity drug data. Story

> IBM out to partner nanoparticle strategy for fighting bacteria. Article

Biotech IT News

> Medidata opens kimono for clinical trial cost study. Report

> PRODUCT UPDATE: Perceptive's DataLabs 5.0 EDC Solution. Story 

> AstraZeneca talks up ePRO tech. News 

> Necessity driving leery pharma "open". Item

> AMAG Pharma opts for cloud over internal infrastructure. Article 

Medical Device News

> Medtronic prevails over Boston Sci in patent suit. Item

> Emerge to target $2B orthopedic trauma market with generic implants. News 

> Abbott reports good news from Absorb study. Report 

> Quest Diagnostics completes Athena buy. Story

> St. Jude's Starks sees 2010 compensation rise 19%. Report 

> SMT raises $10.5M for embolic protection device. News 

And Finally... Johns Hopkins researchers found that men using the cardiac drug digoxin had a 24 percent lower risk for prostate cancer. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.